Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 7,900 shares, a decrease of 86.0% from the March 31st total of 56,600 shares. Based on an average daily volume of 468,400 shares, the days-to-cover ratio is presently 0.0 days.
Bioxytran Price Performance
Bioxytran stock traded down $0.02 during mid-day trading on Friday, reaching $0.12. 88,741 shares of the company traded hands, compared to its average volume of 99,991. Bioxytran has a fifty-two week low of $0.07 and a fifty-two week high of $0.54. The company has a market capitalization of $20.88 million, a price-to-earnings ratio of -4.00 and a beta of -0.83. The firm’s fifty day moving average is $0.12 and its two-hundred day moving average is $0.13.
Bioxytran (OTCMKTS:BIXT – Get Free Report) last released its quarterly earnings data on Friday, March 22nd. The company reported ($0.01) earnings per share for the quarter.
About Bioxytran
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
Read More
- Five stocks we like better than Bioxytran
- What is a Bond Market Holiday? How to Invest and Trade
- 3 Stocks Leading the U.S. Agriculture Comeback
- Election Stocks: How Elections Affect the Stock Market
- How to Use Put Debit Spreads to Profit From Falling Stocks
- 3 Stocks to Consider Buying in October
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.